CSL Behring UK Limited

Hayworth House, Market Place, Haywards Heath, West Sussex, RH16 1DB, UK
Telephone: +44 (0)1444 447 400
Fax: +44 (0)1444 447 403
WWW: http://www.cslbehring.co.uk
Medical Information Direct Line: +44 (0)1444 447 405
Medical Information e-mail: medinfo@cslbehring.com
Customer Care direct line: +44 (0)1444 447 402
Out of Hours contact: +44 (0)1444 447 405

Summary of Product Characteristics last updated on the eMC: 22/09/2010
SPC Privigen 100mg/ml solution for infusion

When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC. For each version, we show the dates it was published on the eMC and the reasons for change.

Updated on 22/09/2010 and displayed until Current
Reasons for adding or updating:
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.4 - Special warnings and precautions for Use
  • Change to section 4.8 - Undesirable Effects
  • Change to section 5.1 - Pharmacodynamic Properties
  • Change to section 5.2 - Pharmacokinetic Properties
  • Change to section 6.2 - Incompatibilities
  • Change to section 6. 3 - Shelf Life
  • Change to section 6. 6 - Instructions for use, handling and disposal
  • Removal of Black Triangle
Date of revision of text on the SPC:   26-Aug-2010
Legal Category:   POM
Black Triangle (CHM):   YES

Free-text change information supplied by the pharmaceutical company

The changes fall into 4 categories:
1) The black triangle has been removed from the SmPC as this is no longer a requirement, but it remains on the promotional material until further notice. 
2) Changes to sections 5.1 & 5.2 are corrections from a previously approved variation
3) Changes to sections 4.2, 4.4, 6.2, 6.3 & 6.6 relate to a variation to include 5% glucose solution as a diluent if dilution is required
4) Changes to sections 4.4 & 4.8 relate to a variation to amend haemolysis wording 
Updated on 04/05/2010 and displayed until 22/09/2010
Reasons for adding or updating:
  • Change to section 6.2 - Incompatibilities
  • Change to section 10 date of revision of the text
  • Addition of link to EMEA website
Date of revision of text on the SPC:   20-Apr-2010
Legal Category:   POM
Black Triangle (CHM):   YES

Free-text change information supplied by the pharmaceutical company

Change to section 6.2 to remove reference to section 6.6 and change the European Medicines Agency details.
Updated on 12/02/2010 and displayed until 04/05/2010
Reasons for adding or updating:
  • Change to section 6. 3 - Shelf Life
  • Change to section 10 date of revision of the text
Date of revision of text on the SPC:   28-Jan-2010
Legal Category:   POM
Black Triangle (CHM):   YES

Free-text change information supplied by the pharmaceutical company

In section 6.3, the shelf life has been changed from 2 to 3 years. 
Updated on 25/09/2009 and displayed until 12/02/2010
Reasons for adding or updating:
  • Introduction of new pack/pack size
Date of revision of text on the SPC:   21-Aug-2009
Legal Category:   POM
Black Triangle (CHM):   YES

Free-text change information supplied by the pharmaceutical company

Addition of 2.5g pack size
Updated on 12/06/2009 and displayed until 25/09/2009
Reasons for adding or updating:
  • Introduction of new pack/pack size
Date of revision of text on the SPC:   07-May-2009
Legal Category:   POM
Black Triangle (CHM):   YES

Free-text change information supplied by the pharmaceutical company

Addition of 2.5g vial
Updated on 04/03/2009 and displayed until 12/06/2009
Reasons for adding or updating:
  • Addition of Black Triangle
Date of revision of text on the SPC:   25-Apr-2008
Legal Category:   POM
Black Triangle (CHM):   YES

Free-text change information supplied by the pharmaceutical company

Addition of black triangle
Updated on 17/12/2008 and displayed until 04/03/2009
Reasons for adding or updating:
  • New SPC for new product
Date of revision of text on the SPC:  
Legal Category:   POM
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company

None provided

Active Ingredients/Generics

 
   human normal immunoglobulin